iBio develops Activin E antibody for obesity; preclinical data shows sub-nanomolar binding

iBio, Inc.

Antibody targeting Activin E for cardiometabolic disorders and obesity, developed with AstralBio Inc.
Preclinical data: sub-nanomolar binding kinetics and complete blockade of Activin E signaling in human adipocytes.
Utilized iBio's AI platform to engineer antibodies targeting five epitopes on Activin E protein.
Corporate presentation updated to reflect the new antibody program; used in investor meetings.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.